Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Free Report) was the target of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 23,500 shares, a decline of 46.2% from the January 31st total of 43,700 shares. Based on an average trading volume of 197,200 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.6% of the shares of the company are short sold.
Aptevo Therapeutics Price Performance
APVO stock opened at $3.82 on Friday. Aptevo Therapeutics has a twelve month low of $3.01 and a twelve month high of $399.60. The business’s 50-day simple moving average is $4.26 and its 200 day simple moving average is $211.69.
Analyst Ratings Changes
Separately, StockNews.com began coverage on shares of Aptevo Therapeutics in a report on Monday, December 9th. They issued a “sell” rating for the company.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Featured Stories
- Five stocks we like better than Aptevo Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 5 Best Gold ETFs for March to Curb Recession Fears
- With Risk Tolerance, One Size Does Not Fit All
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
